Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Trial of AMG 714 in Type II Refractory Celiac Disease
2015-004063-36Phase 2Completed
- Sponsor
- Celimmune
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in refractory celiac disease type II comparing AMG 714 with Placebo (2 arms). Primary endpoint: Immunological Response 1. Started Jan 2016; status: completed.
02
Drugs
ordesekimab
03
Conditions
refractory celiac disease type II
Beyond the preview
Go deeper on 2015-004063-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004063-36.